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’ INTRODUCTION
Up to date, cationic lipids or polycations are widely investi-
gated nonviral gene vectors.14 They form lipoplexes or poly-
plexes with negatively charged plasmid DNA (pDNA), antisense
oligonucleotides (AONs), double stranded RNA (dsRNA) or
small interfering RNA (siRNA).58 PAMAM dendrimers are
special among the polycationic gene vectors.912 The primary
amino groups on PAMAM dendrimer chain termini bind and
compress pDNA into polyplexes. The tertiary amino groups in
PAMAM dendrimer core supply PAMAM dendrimers with
“proton sponge” capacity, which facilitate the endosome escape
of PAMAM polyplexes.1319 PAMAM dendrimers in higher
generations cause more cytotoxicity than the low-generation
ones, while the former produce higher transfection yields.20,21 To
exploit the full potential of PAMAM dendrimer as gene carriers,
it is crucial to develop novel PAMAM dendrimers with high
gene transfer ability but low cytotoxicity. In our recent studies,
oligoamines with different nitrogen densities were applied for
oligoethylenimine (OEI) or poly(propylene imine) (PPI) den-
drimer modification, a positive correlation between oligoamine
chain length and transfection efficiency was found. This was attri-
buted to the increased proton sponge effects of oligo (ethylene
amines) with higher chain lengths.38,45
For gene delivery in vivo, the polyplexes are usually destabi-
lized by serum protein absorption induced aggregation and
physiological salt-triggered dissociation.22 PEG modification
minimizes these disadvantages and elongates the circulation
retention time of polyplexes.23,24 On the other hand, PEG shield-
ing suppresses transfection efficiency by reducing intracellular
uptake and endosome escape of polyplexes.25,26 Targeting ligands
such as serum protein transferrin, antibodies, or growth factors
have been incorporated into polyplexes to obtain higher targeted
cell specificity and recovery the depressed transfection efficacy by
PEG shielding.2729 The epidermal growth factor receptor (EGFR)
is highly expressed in a wide variety of human tumors, such as lung,
breast and hepatocellular cancers.30 The binding of EGF to EGFR
triggers the fast internalization of EGF conjugated polyplexes.31
Our previous studies demonstrated that the EGF-PEG conju-
gated polyethylenimine (EGF-PEG-PEI) polyplexes delivered
pDNAor dsRNA into targeted cells or tumor xenograftmuchmore
efficiently than EGF free ones.3236
With the knowledge from oligoamine-modified OEI/PPI vec-
tors and EGF conjugated PEI polyplexes, we hypothesized that
the transfection efficiency of low generation PAMAM dendri-
mers can be enhanced by introducing oligoamines and EGF
moiety into their chain termini. In the present communication, we
describe the synthesis of an EGF-PEG functionalized PAMAM
lineardendritic architectural copolymer. The PEG-PAMAM
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ABSTRACT:Aim of this study was the site-specific conjugation
of an epidermal growth factor (EGF)-polyethylene glycol (PEG)
chain by click chemistry onto a poly(amido amine) (PAMAM)
dendron, as a key step toward definedmultifunctional carriers for
targeted gene delivery. For this purpose, at first propargyl amine
cored PAMAMdendrons with ester ends were synthesized. The
chain terminal ester groupswere thenmodified by oligoamineswith
different secondary amino densities. The oligoamine-modified
PAMAM dendrons were well biocompatible, as demonstrated
in cytotoxicity assays. Among the different oligoamine-modified
dendrons, PAMAM-pentaethylenehexamine (PEHA) dendron polyplexes displayed the best gene transfer ability. Conjugation of
PAMAM-PEHA dendron with PEG spacer was conducted via click reaction, which was performed before amidation with PEHA.
The resultant PEG-PAMAM-PEHA copolymer was then coupled with EGF ligand. pDNA transfections in HuH-7 hepatocellular
carcinoma cells showed a 10-fold higher efficiency with the polyplexes containing conjugated EGF as compared to the ligand-free
ones, demonstrating the concept of ligand targeting. Overall gene transfer efficiencies, however, were moderate, suggesting that
additional measures for overcoming subsequent intracellular bottlenecks in delivery have to be taken.
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copolymer was prepared by site-specifically conjugating PEG
chain onto PAMAM dendron via click chemistry. After terminal
modification of PAMAM dendron with PEHA, the resultant
PEG-PAMAM-PEHA copolymer was coupled with EGF ligand.
The gene transfer study in HuH-7 cells showed that EGF conju-
gated polyplexes were 10-fold more efficient than the EGF free
ones. To our knowledge, this is the first report to produce ligand
functionalized PEG-PAMAM lineardendritic architectural co-
polymer via click chemistry. The methodology developed in this
study could be easily applied for site-specific conjugation of
different ligands with PAMAM dendrimers.
’MATERIALS AND METHODS
Propargyl amine, 1-chloro-3-aminopropane hydrochloride, methyl
acrylate, toluene, methanol (HPLC grade), deuterium oxide, d-chloro-
form, copper powder, copper bromide (CuBr), pentamethyldiethylene-
triamine (PMDETA), branched polyethylenimine 25 kDa (BPEI), 2,5-
diphenyl-3-(4,5-dimethyl-2-thiazolyl) tetrazolium bromide (MTT), and
oligoamines (ethylenediamine EDA, diethylenetriamine DEA, triethylene-
tetramine TETA, tetraethylenepentamine TEPA, pentaethylenehexamine
PEHA) were obtained from Sigma-Aldrich (Munich, Germany). Linear
PEI 22 kDa (LPEI) was synthesized as described in our recently published
work.36 PDP-PEG-NHS (ortho-pyridyldisulfide-PEG-N-hydroxyl-succini-
mide,Mn 2 kDa) and methyl-PEG-NHS (Mn 2 kDa) were obtained from
Shearwater Polymers (Huntsville, AL, U.S.A.). Mouse epidermal growth
factor (mEGF) was purchased from Serotec (Oxford, England). mEGF-
PDP was prepared by following the method described in elsewhere.33,36
Regenerated cellulose dialysis tubing with different molecular weight cut-
offs (MWCO) were obtained from Spectrum Medical Industries, Inc.
(California, U.S.A.). Cell culture medium, antibiotics, and fetal calf serum
(FCS) were purchased from Life Technologies (Karlsruhe, Germany).
Cell culture lysis buffer and D-luciferin sodium salt were obtained from
Promega (Mannheim, Germany). Plasmid DNA (Photinus pyralis lucifer-
ase under control of the CMV enhancer/promoter, described by Plank
et al.37) was purified with the EndoFree Plasmid Kit fromQiagen (Hilden,
Germany). Water was used as Millipore water (MQ). All other reagents
were analytical grade and used without further treatment.
1H and 13C NMR spectra were recorded on an Eclipse 500 spectro-
meter at 500 and 125 MHz, respectively (JEOL, Tokyo, Japan). Mass
spectra were recorded by fast atom bombardment mass spectra (FAB-
MS, Finnigan, CA, USA) or electrospray-ionization mass spectra (ESI-
MS, Waters Micromass Technologies, Manchester, U.K.). The copoly-
mer molecular weights (Mw,Mn) and their corresponding polydispersity
indexes (PDI, Mw/Mn) were determined by a GPC system (Agilent
Technologies, Waldbronn, Germany), which was equipped with multi-
detectors (refractive index, UV and viscosity detectors), a NOVEMA
10mmprecolumn, and a NOVEMA 300 analytical column (PSS,Mainz,
Germany). An acidic mobile phase was applied for GPC measurement
(0.1 v/v% HCOOH and 0.1 M NaCl in MQ, pH 2.8). The chromatog-
raphy was performed at a flow rate of 1.0 mL 3min
1. Pullulans with
different molecular weights were used as standard samples.38
Preparation of Propargyl-PAMAM Dendrons. In this study,
propargyl-PAMAM dendrons were synthesized according to the proce-
dure reported by Lee and Dong et al.39,40 The experimental details were
shown in Supporting Information. The chemical structure of propargyl-
PAMAM dendron G3.5 was confirmed by 1H NMR spectra and mass
spectra. 1H NMR (CDCl3): δ = 2.14 (s, 1H), 2.322.42 (m, 60H),
2.502.54 (m, 28H), 2.702.82 (m, 60H), 3.203.24 (br m, 28H), 3.44
(s, 2H), 3.65 (s, 48H), 7.08 (br s, 8H), 7.65 (br s, 4H), 7.78 (br s, 2H).MS
(ESI) C137H241N29O46: calcd, 3028.74; found, 1515.88 [M/2 þ 2H].
Terminal Modification of Propargyl PAMAM Dendron
G4.0. The chain termini of PAMAM dendron G3.5 were modified by
different oligoamines including EDA, DETA, TETA, TEPA, and PEHA.
Typically, 100 mg (0.033 mmol) of PAMAMdendron G3.5 was dissolved
in 10 mL of anhydrous methanol. The resultant dendron methanol solu-
tion was added dropwise into 50 mL of oligoamine methanol solution
at oligoamine to ester group molar ratio of 50. The amidation reaction
was continued for three days at room temperature. Afterward, the reac-
tant was purified by dialysis (MWCO 1.0 kDa) against MQ water and
lyophilized to obtain the final product. The yield was around 70%.
Synthesis of PDP-PEG-N3. The 1-azido-3-aminopropane mono-
mer was prepared according to the literature method.41 1H NMR
(CDCl3): δ = 1.17 (br s, 2H), 1.72 (q, 2H) 2.78 (t, 2H), 3.35
(t, 2H). 13C NMR (CDCl3): δ = 32.31(s), 39.22 (s) and 49.06 (s).
MS (FABþ) C3H8N4: calcd, 100.12; found, 101.14 (M
þ þ H).
To synthesize PDP-PEG-N3, a certain amount of PDP-PEG2k-NHS solid
(44 mg, 0.022 mmol) and 1-azido-3-aminopropane (88 mg, 0.88 mmol)
were dissolved in 1.0 mL of anhydrous DMF and reacted for 2 days at
room temperature. Thereafter, the reactant was precipitated by cold
diethyl ether and vacuum-dried to obtain target product of PDP-PEG-
N3 (33 mg, yield 77%).
1H NMR (D2O): δ = 1.75 (m, 2H), 2.482.50
(m, 4H), 2.60 (t, 2H), 2.96 (t, 2H), 3.05 (t, 2H), 3.273.32 (m, 2H),
3.44 (m, 2H), 3.63 (s, 182), 7.30 (t, 1H), 7.80 (m, 2H), 8.35 (t, 1H).
FT-IR (ATR) 2850 (vCH2), 2095(vN3), 1100 cm
1(vCO).
Synthesis of PDP-PEG-PAMAM(G4)-PEHA Conjugate via
Click Chemistry. The PDP-PEG-PAMAM-PEHA conjugate was pre-
pared by a two-step reaction. Defined amounts of PDP-PEG2k-azide
(25 mg, 0.013 mol) and PAMAM dendron G3.5 (35 mg, 0.012 mol)
were dissolved in 2.0 mL of anhydrous ethanol with CuBr (1.8 mg, 0.013
mol) and PMDETA (2.2 mg, 0.013 mol) addition. The mixture was
stirred for 12 h at 40 C water bath. After addition of certain amount of
copper powder, the reaction was continued for additional 12 h.
The ester groups on the PEG-PAMAM dendron were further amino-
lyzed by PEHA according to the procedure described above. The excess
PEHA was removed by dialysis against MQ water overnight (MWCO
3.0 kDa). The free PDP-PEG2k-azide was removed by high performance
liquid chromatography (HPLC) on an
::
Akta Basic system equipped with
a cationic exchange column (Pharmacia Biotech, Uppsala, Sweden).
The void fractions containing PDP-PEG-PAMAM-PEHA conjugate
were pooled and purified by dialyzing against MQwater and subsequent
lyophilization (33 mg, yield 60%). To shield the positive charge on the
polyplex surface, a PDP-free PEG2k-PAMAM-PEHA analog was syn-
thesized as described above.
Preparation of EGF-PEG Functionalized PAMAM-PEHA
Conjugate. The pyridyldisulfide group in the PDP-PEG2k-PAMAM-
PEHA conjugate was reduced with 50 molar equiv of DTT in 20 mM
Hepes buffer (pH 7.4). The resultant HS-PEG-PAMAM-PEHA con-
jugate was purified by HPLC equipped with a G-25 superfine column
(Sephadex G25 superfine, Amersham Biosciences, U.S.A.) equilibrated
in 20 mMHepes buffer (pH 7.4) under argon protection. The copolymer
and sulfhydryl group concentrations in the collected solution were quanti-
fied by 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay and Ellman’s
test with PAMAM-PEHA and cysteine controls, respectively. EGF-PEG-
PAMAM-PEHA conjugate was synthesized by following a protocol
described elsewhere.33,36 In brief, 200 μL of HS-PEG-PAMAM-PEHA
Hepes solution (0.061 μmol of free sulfhydryl group) was mixed with
1.5-fold excess of mEGF-PDP (0.62 mg, 0.10 μmol in 1.0 mL of 30%
ethanolHepes buffer, pH 7.4) at room temperature. The reaction was
continued for 24 h under argon protection, and then the reaction mixture
was directly loaded on a cationic exchange column to remove free mEGF
moiety.After dialysis against 1mMHepesbuffer (pH7.4) (MWCO1.0 kDa)
overnight, the solution was concentrated by speed evaporator at room
temperature. The polymer concentration was determined by TNBS assay.
Polyplex Preparation. pDNA-loaded polyplexes were prepared
by adding the polymer solution to pDNA solution at indicated poly-
cation to pDNA weight ratios (c/p ratios). Polyplexes were allowed to
incubate for at least 20 min at room temperature prior to use. HBG
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buffer (20 mM Hepes buffer with 5% (wt/v) glucose addition, pH 7.4)
was used for polyplex preparation.
Particle Size and Zeta-Potential. The particle size and zeta-
potential of the prepared polyplexes inHBGweremeasured by Zetasizer
Nano ZS (Malvern Instruments, Herrenberg, Germany) equipped with
a 4mWHeNe laser at a wavelength of 633 nm at 25 C. Zeta-potential
measurement was performed in a folded capillary cell (Malvern Instru-
ments, Herrenberg, Germany). The presented data were means out of
three independent measurements.
Cell Culture.Neuro2A neuroblastoma cells (ATCCCCl-131) were
purchased from DSMZ (Braunschweig, Germany). B16F10 murine
melanoma cells were kindly provided by Texas Medical Center (Houston,
TX, U.S.A.). Both Neuro2A and B16F10 cells were cultured in DMEM
(1.0 g 3L
1 glucose) supplemented with 10% FCS, 100U 3mL
1 penicillin
and 100 μg 3mL
1 streptomycin. HuH-7 hepatocellular carcinoma cells
(JCRB 0403, Tokyo, Japan) were cultured in DMEM/HAM F-12 (1:1)
medium containing 10% FCS, 100 U 3mL
1 penicillin and 100 μg 3mL
1
streptomycin as described in our previous study.25 All the cells were cultured
in 37 C incubator with 5% CO2 supply and humidified atmosphere.
Cytotoxicity Assay. The metabolic activity of the cells incubated
with polymer solutionswas determined byMTTassay. B16F10 cells were
seeded in 96-well tissue culture plates (TPP, Transdingen, Switzerland)
Figure 1. Oligoamine modification of propargyl-PAMAMdendron at chain termini. (A) Reaction scheme for terminal modification of PAMAMdendrons;
(B) Representative chemical structure of oligoamine-modifiedG4.0 PAMAMdendrons (n= 0,DEA; n= 1,DETA; n= 2, TETA; n= 3, TEPA; n= 4, PEHA).
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at a density of 5000 cells per well in 100 μL of cell culture medium.
Polymer solutions at different final concentrations were added when
cells reached 6080% confluence. The cell culture medium was re-
placed directly after 4 h polymer incubation. MTT solution (10 μL per
well, 5.0 mg 3mL
1 in phosphate-buffered saline buffer, pH 7.4) was added
24 h later. The medium was replaced by 100 μL of DMSO after 2 h MTT
incubation. The optical absorbance was measured at 590 nm (reference
wavelength 630 nm) by a microplate reader (Spectraflour Plus, Tecan
Austria GmbH, Austria).42 The metabolic activity of the polymer-treated
cells was expressed as relative cell viability compared to that of untreated
cell control.
Gene Transfer In Vitro. The gene transfer study in vitro was done
in 96-well tissue culture plates. In a typical transfection experiment,
B16F10 cells were seeded at a density of 5000 cells per well, HuH-7
and Neuro2A cells were both seeded at a density of 10000 cells per well,
respectively. A total of 24 h later after cell seeding, 20 μL of polyplex
solution containing 200 ng of pDNAwas added. The cell culture medium
was changed after 4 h polyplex incubation. The luciferase activity of the
polyplex treated cells was measured 24 h later after polyplex addition with
a luminometer (Lumat LB 9507, Berchtold, Germany) as described pre-
viously.43 All transfection operations were done in five replicates. LPEI
and BPEI polyplexes were prepared at polymer to pDNA weight ratio of
0.8 for all three different cell lines.44
EGFR overexpressing HuH-7 cells and control cell line Neuro2A
(low in EGFR) were selected for targeted transfection studies. The EGF
incorporated (EGF (þ)) PEI polyplexes were prepared in optimized
formulation and applied as positive controls: EGF-PEG10k-LPEI22/
3PEG-LPEI22/BPEI25 = 13/22/100. The EGF free (EGF (-)) PEI
polyplex controls were prepared in composition of 3PEG-LPEI22/
BPEI25 = 25/100 (same PEG ratio).34 Two EGF contents (5% and
10%) were selected to optimize the transfection condition of EGF in-
corporated PAMAM polyplexes.
’RESULTS AND DISCUSSION
Synthesis and Chemo-Physical Characterization of
PAMAMDendrons.To synthesize oligoamine-modified PAMAM
dendrons as demonstrated in Figure 1, PAMAM dendron in
generation 3.5 with propargyl amine core and ester ends was first
prepared by following the literature method.46 The chemical
structure and molecular weights of the prepared propargyl-
PAMAM dendrons were examined by 1H NMR spectra (Figures
SI 1 and SI 2) and mass spectra (Table SI 1), respectively. The
molecular weights of propargyl-PAMAM dendrons determined by
mass spectra were inconsistent with their theoretical molecular
weights, indicating the successful synthesis of designed propargyl-
PAMAM dendrons. The terminal ester groups of PAMAM den-
dron were then substituted by different oligoamines (DEA, DETA,
TETA, TEPA, and PEHA; see Figure 1). The chemical composi-
tions and corresponding substitution degrees of oligoamine-
modified PAMAM dendrons were examined by 1H NMR spectra.
As shown in Figure 2A and Figure SI 1, the 1H NMR peak around
3.6 ppm disappeared, indicating the complete substitution of the
ester groups. The oligoamine substitution degrees were deter-
mined by 1H NMR spectra and the results were collected in
Table 1. A substitution degree of 99%was found in DEA-modified
dendron.The substitution degrees decreasedwhen the oligoamine
chain lengths were extended. This might be caused by the loop
formation during the amidation reaction.46 The molecular weights
(Mw and Mn) of oligoamine-modified PAMAM dendrons were
measured by GPC examination. The molecular weights of
PAMAM dendrons increased when modified with DEA, DETA,
or TETA, but decreased when modified with TEPA or PEHA
comparedwith that of EDAended one (seeTable 1). This wasmost
likely attributed to the condensed topological structure of PAMAM
dendrons with longer oligoamine terminal chains.47 The molecular
weight polydispersity (PDI) of DETA-, TETA-, TEPA-, or PEHA-
modified PAMAMdendron became broader compared to that of
PAMAM-EDA or PAMAM-DEA dendron, indicating the occur-
rence of intermolecular cross-linking during the amidation
process. The termini secondary amino densities were calculated
according to the 1H NMR spectra determined substitution
degrees. As shown in Table 1, the number of secondary amino
groups increased when oligoamine chain was elongated. This corre-
lated with the secondary amine density in each oligoamine chain.
The cytotoxicity of the surface-modified PAMAMdendrons in
B16F10 cells was examined byMTT assay. The cells treated by
LPEI lost 90% of their metabolic activity at a polymer concen-
tration of 25 μg 3mL
1. The PAMAM dendron treated cells kept
more than 80% of their metabolic activity at polymer concentration
of 400 μg 3mL
1. No significant difference was found among
different oligoamine-modified PAMAM dendrons (see Figure 2B).
This suggested that terminal modification of PAMAM dendron
with different oligoamines did not enhance cytotoxicity of PAMAM
Figure 2. 1H NMR spectra characterization and cytotoxicity assay for
oligoamine-modifiedPAMAMdendrons. (A) 1HNMRspectra of terminal-
modified PAMAM dendrons; (B) Cytotoxicity assay for oligoamine-
modified PAMAM dendrons in B16F10 cells. The arrows indicated
the presence of the propargyl group in the modified PAMAM dendrons.
The cells kept metabolic activity over 90%, suggesting the low cytotoxi-
city of oligoamine-modified G4 PAMAM dendrons.
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dendrimers. The transfection property of PAMAM dendrons was
examined in both B16F10 and Neuro2A cells. As shown in
Figure 3A,B, at different polymer to pDNAweight ratios, allmodified
PAMAM dendron polyplexes transfer pDNA efficiently into both
cell lines. The B16F10 andNeuro2A cells treated by the PAMAM
polyplexes both showed metabolic activity higher than 90% (see
Figure 3C,D), suggesting that PAMAM polyplexes with different
oligoamine modification induced noncytotoxic effects in transfected
cells. At a defined polymer to pDNA weight ratio, PAMAM-PEHA
polyplexes displayed the highest transfection efficiency in both
B16F10 andNeuro2A cells.We took it as the optimal composition
for the next step of EGF-PEG functionalization.
EGF-PEG Functionalization of PAMAM-PEHADendron.Up
to date, in reported literature on PEG-PAMAM lineardendritic
architectural copolymers, they were synthesized either by
growing PAMAM dendron from the amino end of PEG
chain48,49 or by grafting PEG chain onto PAMAM chain termini
with NHS ester.50 However, the latter resulted in conjugations at
random sites. In this study, we aimed to develop site-specific
EGF-PEG functionalized PAMAM-PEHA conjugate for targeted
gene delivery. To do that, PEG-PAMAM copolymer needed to
be prepared first. Cu(I)-catalyzed Huisgen [2 þ 3] dipolar
cycloaddition reaction or so-called “click chemistry” is of high
conversion rate and specificity.51 Thus, we applied click reaction
to prepare PEG-PAMAM-PEHA copolymer. Because the click
reaction had to be performed before the oligoamine coupling
(because the polyamines were found to be incompatible with
efficient click chemistry, our unpublished results), the synthesis
procedure was optimized and shown in Figure 4. First, the azido
group was coupled onto one end of PEG chain by reacting of
Table 1. Molecular Parameters of Oligoamine-Modified G4 PAMAM Dendrons
samples suba (%) theoretical Mw
b (103) determined Mwc (103) determined Mnc (103) PDI (Mw/Mn) secondary amino groupsd
G4-EDA 99 3.48 6.27 3.46 1.81 0
G4-DETA 86 4.17 5.21 4.00 1.30 14
G4-TETA 84 4.86 8.94 4.05 2.20 27
G4-TEPA 82 5.55 7.46 4.93 1.51 39
G4-PEHA 71 6.24 5.92 4.67 1.27 45
a Sub = degree of substitution (oligoamine units/16), calculated from 1HNMR integration; bMw was calculated with 100% substitution degree.
c Mw and
Mn were determined by GPC measurement.
dNumber of secondary amino groups, calculated from integration of 1H NMR peak area.
Figure 3. Luciferase activity and metabolic activity of B16F10 (A, C) and Neuro2A cells (B, D) treated by oligoamine-modified PAMAM dendron
polyplexes. The polyplexes were prepared in HBG buffer, and 200 ng of pDNA per well was applied for 96-well tissue culture plate. The cell culture
medium was changed 4 h after polyplex addition. The relative luciferase activity and metabolic activity of polyplexes treated cells were measured 24 h
later. Presented data showed the average readout of five replicates (n = 5, *p < 0.01).
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ester NHS with 1-azido-3-aminopropane, and then the PEG
chain was conjugated with ester group ended PAMAM dendron
through click reaction between azido and propargyl groups. For
conversion into the EGF-PEG-PAMAM-PEHA conjugate, the
resultant PEG-PAMAM linear-dendron architectural copolymer
was aminolyzed with PEHA and further conjugated with EGF
(mEGF) ligand. Our previous studies on EGF-PEG-PEI conjugates
showed that PEG spacer with relatively low molecular weight
(Mn 2 kDa) was sufficiently high to shield PEI-based pDNA
polyplexes and obtain an EGF receptor specific effect. Higher
molecular weight PEG (Mn 5 kDa) strongly reduced transfection
activity of EGF-PEG-PEI polyplexes.34,36 Therefore, we used
PDP-PEG-NHS (Mn 2 kDa) to prepare the EGF-PEG-PAMAM-
PEHA conjugate.
The chemical structures of the intermediate products, such as
PDP-PEG-azide and PDP-PEG-PAMAM-PEHAwere character-
ized by 1HNMR spectra examination (see Figures SI 5 and SI 6).
The occurrence of the click reaction was confirmed by the pre-
sence of the proton signal assigned to the trizole group. For EGF
coupling, thiol group on PEG spacer of PDP-PEG-PAMAM-
PEHA conjugate was first released by DTT treatment, EGF li-
gand was then covalently coupled to PEG spacer via a disulfide
bond bridge. The thiol group concentration after DTT reduction
was determined to be 1.15mMper gram of polycation (mM 3 g
1)
by combined Ellman’s test and TNBS assay. The calculated mole-
cular weight of PEG-PAMAM-PEHA conjugate was 8235.20
Da (the theoretical molecular weight of PAMAM-PEHA den-
dron plus the molecular weight of PEG; see Table 1). Thus, we
estimated that there was one thiol group on each PEG-PAMAM-
PEHA chain. The EGF coupling reaction was monitored by
determining the concentration of 2-pyridinethione produced
during the reaction (UVabs 344 nm).
52 As shown in Figure SI
7, the determined conversion percentages matched the theore-
tical ones well at four different EGF-PDP to copolymer feeding
ratios, indicating the high conjugation efficiency between HS-
PEG-PAMAM-PEHA and mEGF-PDP. To prepare the final
EGF-PEG-PAMAM-PEHA conjugate, 1.5-fold excess of mEGF-
PDP over copolymer was applied in the conjugation. The un-
reacted mEGF-PDP was removed by cation-exchange chromatog-
raphy to obtain purified mEGF-PEG-PAMAM-PEHA conjugate.
EGFR-EGF Interaction Mediated Targeted Gene Delivery.
EGF ligand modification improved the transfection efficiency of
PEI polyplexes by 10100 folds due to the accelerated inter-
nalization of polyplexes via EGFR-EGF interaction.32,33 To
evaluate the influence of EGF conjugation on the gene transfer
property of chain terminal modified PEG-PAMAM dendron, the
transfection study was conducted in EGFR overexpressed HuH-
7 cells (as shown in Figure 5A). With the optimized polyplex
formulation, the EGF conjugated BPEI polyplexes displayed
12.6-fold higher luciferase activity than that of the EGF-free
ones, being in good agreement with our previous observations.34
In the case of PAMAM polyplexes, two polyplex compositions
and three different polymer to pDNA weight ratios were tested
(see Figure SI 8). At the optimized polymer to pDNA weight
ratio of 16 (polyplex composition: PAMAM/PEG-PAMAM/
EGF-PEG-PAMAM = 5/15/80), the HuH-7 cells treated by
Figure 4. Design and synthesis of EGF functionalized PEG-PAMAM-PEHA conjugate. (A) Synthesis of EGF-PEG functionalized PAMAM-PEHA
dendron via click chemistry: (a) anhydrous DMF, RT, 24 h; (b) ethanol, CuBr/Cu/PMDETA, 40 C, 24 h; (c) DTT, 20 mM Hepes buffer (pH 7.4),
24 h; (d) 30% ethanolHepes buffer (20 mM, pH 7.4), RT, 24 h. (B) Proposed structure of the EGF-PEG-PAMAM-PEHA conjugate. The PEHA-
modified PAMAM dendron was taken as the optimal for PEG conjugation and EGF functionalization.
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EGF(þ) PAMAM polyplexes showed 10-fold enhancement of
luciferase activity as compared to that treated by EGF(-) ones.
We also examined the transfection efficiency of PAMAM poly-
plexes with higher PEG-PAMAM percentage of 25%; only 1.5-
fold higher luciferase expression was found compared to its
parental PEG-PAMAM polyplexes, which might be due to the
increased shielding effect on the polyplex surface with higher PEG
density. To clarify the contribution of EGF-EGFR interaction on
the improved gene transfer efficiency of PAMAM polyplexes,
Neuro2A cells with low EGFR expression was selected as negative
control. As shown in Figure 5B, Neuro2A cells treated with PEG
shielded polyplexes with or without EGF coupling expressed equal
or less luciferase protein compared to those treated with parental
PAMAM polyplexes. This was most likely caused by the stable
PEGylation, which had been demonstrated in our previous study
to negatively affect endosomal escape.25,53
To elucidate the influence of polyplex particle size and surface
charge on the gene transfer ability of EGF conjugated PAMAM
polyplexes, the particle size and zeta-potential of the polyplexes
prepared at the optimized compositions were measured (see
Figure SI 9). BPEI polyplexes with or without EGF coupling all
showed similar particle size around 100 nm due to the strong
pDNA binding and compressing ability of BPEI. The particle size
of PAMAM polyplexes was about 200 nm. The particle size in-
creased up to 340 nm with 10% PEG conjugation and 10% EGF
coupling, which might be caused by the reduced pDNA com-
pressing ability of PAMAM polyplexes after PEG and EGF in-
corporation. The surface charge of BPEI polyplexes was reduced
by PEG conjugation. The PAMAM polyplexes lost half of their
surface positive charge by incorporating 20% of PEG-PAMAM-
PEHA (from þ15 to þ8 mV). The surface charge of 10%
EGF conjugated PEG-PAMAM-PEHA polyplexes was around þ
10 mV. Considering that EGF(þ) PAMAM polyplexes treated
EGFR-low Neuro2A cells produce a comparable or lower trans-
fection yield compared to that treated by EGF(-) one, the slight
difference in surface charge was unlikely to cause the higher
luciferase activity of EGF-PEG polyplexes transfected HuH-7
cells. Together with the transfection data shown in Figure 2A, the
improved transfection yield of EGF(þ) polyplexes over that of
EGF(-) ones in HuH-7 cells most likely is caused by the EGF-
EGFR interaction.
The main aim of this study, applying click chemistry for site-
specific conjugation of ligand-PEG to a PAMAM-PEHA conju-
gate for targeted gene delivery, was demonstrated and confirmed
by the transfection data. However, the overall transfection
efficiency was not as high enough as we expected for successful
application. One of the possible pitfalls of the concept might be
sterical inaccessibility of the EGF targeting ligand for EGFR. The
applied mEGF is slightly acidic (isoelectric point around 5) and
not basic; therefore, interaction with pDNA can be ruled out at
physiological condition. In theory, EGF might interact with
the cationized PAMAM polymer. However, as analogous EGF
conjugates with various (linear and branched) types of poly-
cationic PEI had been successfully applied before (see Figure 5A
and literature), this should not result in major problems with
targeting. Moreover, attachment of EGF ligand to PAMAM-
PEHA dendron with a PEG spacer should prevent it being buried
in the core of polyplexes.
Notably, the EGF-PEG-PAMAM-PEHA polyplexes produced
lower transfection rates in HuH-7 cells than in Neuro2A cells in
general, indicating the largest bottleneck in the pDNA delivery
process was not in cell binding (with or without EGFR medi-
ation) but in a subsequent intracellular delivery step, such as
endosomal escape or nuclear transport.31 The situation might
even be more complex for targeted gene delivery in vivo. The
polyplexes with suitable particle size had to first accumulate in
tumor site, usually passively via enhanced penetration and reten-
tion (EPR) effect.54 In related work, ligands had not significantly
altered tumor accumulation but intracellular uptake and activity.55
The EGF-EGFR interaction would be expected to locally improve
the internalization of polyplexes.31
In sum, further modifications have to be made for overcoming
subsequent gene delivery steps after receptor-mediated targeted
cell binding. Bioreversible PEGylation might be one possible
solution.25,53 PAMAM dendrimer in higher generations usually
generate improved transfection yield via enhanced endosome
escape capacity.20 Alternatively, the transfection efficiency of our
developed EGF-PEG-PAMAM-PEHA polyplexes could possibly
Figure 5. pDNA transfection study of EGF-PEG-PAMAM-PEHA
polyplexes in (A) HuH-7 and (B) Neuro2A cells. At optimized polyplex
composition (EGF-PEG-PAMAM-PEHA/PEG-PAMAM-PEHA/
PAMAM-PEHA = 5/15/80, polymer to pDNA weight ratio of 16),
10-fold higher luciferase protein expression was detected in HuH-7 cells
compared to that of EGF free ones. EGF(þ): polyplexes with PEG
shielding and EGF conjugation; EGF(-): polyplexes with PEG shielding
only (n = 5, *p < 0.01).
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be improved by selecting PAMAM dendrons with higher gen-
erations than that applied in current study, with the PEG
shielding preventing enhanced cytotoxicity.
’CONCLUSION
In this study, a novel synthetic strategy via click chemistry
was developed for site-specific EGF-PEG functionalization of
PAMAM dendron. The impact of chain terminal modification
on the transfection properties of PAMAM dendrons was investi-
gated. The oligoamines with higher secondary amino group
densities resulted in higher gene transfer efficiency, which might
attribute to the improved proton sponge capacity. The PAMAM-
PEHA dendron structure was selected as basis for incorporation
of EGF-PEG via click chemistry. Click chemistry had to be
performed before PEHA incorporation. The EGF-PEG functio-
nalized PAMAM-PEHA dendron polyplexes displayed selec-
tively improved gene transfer ability in EGFR overexpressing
HuH-7 cells. Further modifications will be required to optimize
the transfection efficiency of the EGF functionalized PAMAM
polyplexes.
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